Attached files

file filename
EX-32.2 - EX-32.2 - MICRON SOLUTIONS INC /DE/micr-20180630xex32_2.htm
EX-32.1 - EX-32.1 - MICRON SOLUTIONS INC /DE/micr-20180630xex32_1.htm
EX-31.2 - EX-31.2 - MICRON SOLUTIONS INC /DE/micr-20180630xex31_2.htm
EX-31.1 - EX-31.1 - MICRON SOLUTIONS INC /DE/micr-20180630xex31_1.htm











UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 10‑Q



 Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2018 or



Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ______ to ______

 

001-9731

(Commission file No.)



Micron Solutions, Inc.

(Exact name of registrant as specified in its charter)





 

 

DELAWARE

 

72‑0925679

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. employer identification no.)



25 Sawyer Passway

Fitchburg, Massachusetts  01420

(Address of principal executive offices and zip code)

 

(978) 345-5000

(Registrant's telephone number, including area code)



_________________________________________________________________

(Former name, former address and former fiscal year, if changed from last report)

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes    No 



Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes    No 



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company”  in Rule 12b-2 of the Exchange Act. (Check one):





 

 

 

Large Accelerated filer  

Accelerated filer  

Non‑Accelerated filer  

Smaller reporting company  

Emerging growth company  



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes    No 

 

As of August 13, 2018 there were 2,850,177 shares of the Company’s common stock outstanding.







 


 

Micron Solutions, Inc. and Subsidiary

TABLE OF CONTENTS



 



 

PART I - CONDENSED FINANCIAL STATEMENTS

Item 1.  Condensed Consolidated Financial Statements (unaudited) 



Micron Solutions, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

(unaudited)









 

 

 

 

 

 



 

 

 

 

 

 



 

June 30,

 

December 31,



 

2018

 

2017

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

 —

 

$

606,988 

Restricted cash

 

 

 —

 

 

350,000 

Trade accounts receivable, net of allowance for doubtful accounts of $40,000 at June 30, 2018 and December 31, 2017, respectively

 

 

3,052,691 

 

 

2,595,248 

Inventories

 

 

3,645,152 

 

 

3,413,199 

Prepaid expenses and other current assets

 

 

246,474 

 

 

460,954 

Total current assets

 

 

6,944,317 

 

 

7,426,389 

Property, plant and equipment, net

 

 

5,236,305 

 

 

5,744,039 

Assets held for sale, net

 

 

688,750 

 

 

688,750 

Intangible assets, net

 

 

53,224 

 

 

55,133 

Other assets

 

 

4,135 

 

 

10,289 

Total assets

 

$

12,926,731 

 

$

13,924,600 

Liabilities and Shareholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Revolving line of credit

 

$

1,307,954 

 

$

1,879,047 

Term notes payable, current portion

 

 

390,709 

 

 

367,779 

Subordinated promissory notes, current portion

 

 

 —

 

 

350,000 

Accounts payable

 

 

1,326,070 

 

 

1,534,349 

Accrued expenses and other current liabilities

 

 

426,793 

 

 

320,065 

Contract liabilities, current portion

 

 

736,570 

 

 

426,457 

Total current liabilities

 

 

4,188,096 

 

 

4,877,697 

Long-term liabilities:

 

 

 

 

 

 

Term notes payable, non-current portion

 

 

3,767,167 

 

 

3,978,415 

Total long-term liabilities

 

 

3,767,167 

 

 

3,978,415 

Total liabilities

 

 

7,955,263 

 

 

8,856,112 

Commitments and Contingencies

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued

 

 

 —

 

 

 —

Common stock, $0.01 par value; 10,000,000 shares authorized; 3,926,491 issued, 2,850,177 outstanding at June 30, 2018 and 3,926,491 issued, 2,839,274 outstanding at December 31, 2017

 

 

39,265 

 

 

39,265 

Additional paid-in-capital

 

 

11,565,392 

 

 

11,532,207 

Treasury stock at cost, 1,076,314 shares at June 30, 2018 and 1,087,217 shares at December 31, 2017

 

 

(2,937,046)

 

 

(2,966,798)

Accumulated deficit

 

 

(3,696,143)

 

 

(3,536,186)

Total shareholders’ equity

 

 

4,971,468 

 

 

5,068,488 

Total liabilities and shareholders’ equity

 

$

12,926,731 

 

$

13,924,600 



See accompanying notes to condensed consolidated financial statements.

 

1


 

Micron Solutions, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(unaudited)







 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Six Months Ended



 

June 30,

 

June 30,



 

2018

 

2017

 

2018

 

2017

Net sales

 

$

5,320,426 

 

$

5,390,726 

 

$

10,439,474 

 

$

10,655,703 

Cost of sales

 

 

4,442,606 

 

 

5,008,889 

 

 

8,830,294 

 

 

9,620,492 

Gross profit

 

 

877,820 

 

 

381,837 

 

 

1,609,180 

 

 

1,035,211 



 

 

 

 

 

 

 

 

 

 

 

 

Selling and marketing

 

 

204,036 

 

 

234,820 

 

 

394,576 

 

 

500,693 

General and administrative

 

 

529,092 

 

 

552,678 

 

 

1,133,127 

 

 

1,169,508 

Research and development

 

 

26,801 

 

 

28,344 

 

 

54,722 

 

 

57,640 

Total operating expenses

 

 

759,929 

 

 

815,842 

 

 

1,582,425 

 

 

1,727,841 



 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from operations

 

 

117,891 

 

 

(434,005)

 

 

26,755 

 

 

(692,630)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(96,016)

 

 

(87,429)

 

 

(193,028)

 

 

(151,330)

Other income, net

 

 

11,806 

 

 

9,981 

 

 

20,307 

 

 

34,070 

Total other expense, net

 

 

(84,210)

 

 

(77,448)

 

 

(172,721)

 

 

(117,260)

Net income (loss) before income tax provision (benefit)

 

 

33,681 

 

 

(511,453)

 

 

(145,966)

 

 

(809,890)

Income tax provision (benefit)

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Net income (loss) 

 

$

33,681 

 

$

(511,453)

 

$

(145,966)

 

$

(809,890)

Comprehensive income (loss)

 

 

33,681 

 

 

(511,453)

 

$

(145,966)

 

$

(809,890)

Earnings (loss) per share - basic

 

$

0.01 

 

$

(0.18)

 

$

(0.05)

 

$

(0.29)

Earnings (loss) per share - diluted

 

$

0.01 

 

$

(0.18)

 

$

(0.05)

 

$

(0.29)

Weighted average common shares outstanding - basic

 

 

2,847,642 

 

 

2,820,999 

 

 

2,844,889 

 

 

2,819,915 

Weighted average common shares outstanding - diluted

 

 

2,855,101 

 

 

2,820,999 

 

 

2,844,889 

 

 

2,819,915 



 

 

 

 

 

 

 

 

 

 

 

 



See accompanying notes to condensed consolidated financial statements.



 

2


 

Micron Solutions, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(unaudited)







 

 

 

 

 

 



 

 

 

 

 

 



 

Six Months Ended



 

June 30,



 

2018

 

2017

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(145,966)

 

$

(809,890)

Adjustments to reconcile net loss to net cash provided by (used in)
operating activities:

 

 

 

 

 

 

Gain on sale of property, plant and equipment

 

 

 —

 

 

(21,554)

Depreciation and amortization

 

 

767,605 

 

 

803,217 

Non-cash interest expense

 

 

31,047 

 

 

16,753 

Change in allowance for doubtful accounts

 

 

 —

 

 

12,000 

Share-based compensation expense

 

 

62,937 

 

 

32,417 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(457,443)

 

 

(1,176,664)

Inventories

 

 

(308,214)

 

 

(194,180)

Prepaid expenses and other current assets

 

 

186,311 

 

 

4,159 

Other non-current assets

 

 

2,000 

 

 

145,603 

Accounts payable

 

 

(208,279)

 

 

866,811 

Accrued expenses and other current liabilities

 

 

125,061 

 

 

117,361 

Contract liabilities, current portion

 

 

310,113 

 

 

36,909 

Other non-current liabilities

 

 

 —

 

 

(156,953)

Net cash provided by (used in) operating activities

 

 

365,172 

 

 

(324,011)

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property, plant and equipment

 

 

(181,702)

 

 

(759,546)

Proceeds from sale of property, plant and equipment

 

 

 —

 

 

23,200 

Cash paid for patents and trademarks

 

 

 —

 

 

(15,296)

Net cash provided by (used in) investing activities

 

 

(181,702)

 

 

(751,642)

Cash flows from financing activities:

 

 

 

 

 

 

Proceeds from (payments on) revolving line of credit, net

 

 

(571,093)

 

 

884,205 

Proceeds from equipment line of credit

 

 

 —

 

 

402,281 

Payments on term notes payable

 

 

(190,476)

 

 

(253,145)

Payments of debt issuance costs

 

 

(28,889)

 

 

 —

Payment on subordinated debt

 

 

(350,000)

 

 

 —

Net cash provided by (used in) financing activities

 

 

(1,140,458)

 

 

1,033,341 

Net decrease in cash and cash equivalents and restricted cash

 

 

(956,988)

 

 

(42,312)

Cash and cash equivalents and restricted cash, beginning of period

 

 

956,988 

 

 

380,381 

Cash and cash equivalents and restricted cash, end of period

 

$

 —

 

$

338,069 







 

 

 

 

 

 



 

 

 

 

 

 



 

Six Months Ended



 

June 30,

Supplemental Cash Flow Information

 

2018

 

2017

Cash paid for interest

 

$

162,775 

 

$

138,279 



 

 

 

 

 

 

Non-cash activities:

 

 

 

 

 

 

Issuance of treasury stock for directors fees

 

$

39,750 

 

$

11,250 

Adjustment to accumulated deficit for change in accounting principle (Note 2)

 

$

(13,991)

 

$

 —



See accompanying notes to condensed consolidated financial statements.

 

 

1.  Basis of Presentation and Accounting Policies



The condensed consolidated financial statements (the "financial statements") include the accounts of Micron Solutions, Inc.® (“Micron Solutions”) and its subsidiary, Micron Products, Inc.® ("Micron" and together with Micron Solutions, the “Company”).  All intercompany balances and transactions have been eliminated in consolidation.



The financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC").  Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been omitted pursuant to such rules and regulations.  These financial statements and related notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 26, 2018.



The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The Company's balance sheet at December 31, 2017 has been derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP for complete financial statements.



The information presented reflects, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates. 



Recent Accounting Pronouncements



In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s financial statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s financial statements.



In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. The standard retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of operations and a consolidated statement of cash flows is largely unchanged from previous GAAP.  The amendments in this standard are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted.   



As of the date of this report, the Company is the lessee of office equipment in a single operating lease and is the lessee of a parking lot.  The Company is not a lessor in any arrangements.  The Company is evaluating other supplier relationships to determine if such arrangements constitute a lease per this guidance.  The Company does not expect any material impact on reporting or on the results of operations. 



Operating matters and liquidity



On December 29, 2017, the Company entered into a three-year asset based credit and security agreement (“credit agreement”), with a Massachusetts trust company, replacing the credit facility with the Company’s previous lender.  The credit agreement includes a revolving line of credit and term loans as further described in Note 7.  The agreement provides for daily cash sweeps against the revolver.



In addition to providing funds to discharge all the indebtedness with the Company’s previous lender, the credit agreement provided $450,000 designated to discharge the outstanding subordinated promissory notes.  On December 29, 2017, one subordinated note in the principal balance of $100,000 was discharged in full.  The remaining five subordinated notes totaling an aggregate principal balance of $350,000 were discharged on January 2, 2018.



At June 30, 2018, the Company identified certain conditions and events which in the aggregate required management to perform an assessment of the Company’s ability to continue as a going concern. These conditions, despite the profitable quarter ended June 30, 2018, included the Company’s recurring losses from operations and the resulting reliance on outside financing to support operations.



Management’s analysis includes forecasting future revenues and cash flows, taking into consideration past performance and the requirements under the credit agreement. Revenue and cash flow forecasts are dependent on the Company’s ability to fill booked orders from existing customers, and its ability to close new and expanded business. Based on management’s analysis, the Company expects to generate sufficient cash flows to fulfill its payment obligations over the next twelve months from the date these financial statements were issued.

 

2.  Change in Accounting Principle



Revenue Recognition



The Company adopted ASU No. 2014-09, “Revenue from Contracts with Customers, Topic 606” (“Topic 606”) effective January 1, 2018 using the modified retrospective approach.  Under the modified retrospective method, a cumulative effect of initially applying the new standard is recorded as an adjustment to the opening balance of retained earnings at the date of initial application.  By electing to use this method, there is no restatement of the comparative periods presented (i.e., interim periods and fiscal year ending 2017). As permitted by Topic 606 transition guidance (outlined below), the Company has elected to apply the new standard only to contracts that were not completed contracts at the date of initial application, and therefore, the Company only evaluated those contracts that were in-process and not completed before January 1, 2018.



As a result of the initial application of Topic 606, the Company made an adjustment to its beginning accumulated deficit of ($13,991) to recognize the remaining deferred revenue ($18,333) and deferred costs ($32,324) recorded as of December 31, 2017 relative to certain completed tooling sales. 



Beginning January 1, 2018, the Company applied Topic 606 using the five step approach outlined in the guidance:  (1) Identify contracts with the customer, (2) Identify the performance obligations in the contract, (3) Determine the transaction price, (4) Allocate the transaction price to the performance obligations in the contract, and (5) Recognize revenue when (or as) the entity satisfies the performance obligations.



The Company reviewed its supply and manufacturing agreements with customers as well as the related purchase orders under these agreements.  The Company also reviewed its customer relationships and purchase orders with those customers with which the Company has no formal supply agreement.



The Company determined that customer purchase orders represent contracts with a customer.  For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations.



Shipping and handling activities for which the Company is responsible are not a separate promised service but instead are activities to fulfill the entity’s promise to transfer goods.  Shipping and handling fees will be recognized at the same time as the related performance obligations are satisfied.



The Company determines the transaction price as the amount of consideration it expects to receive in exchange for transferring promised goods or services to the customer.  If a contract includes a variable amount, such as a rebate, then the Company estimates the transaction price using either the expected value or the most likely amount of consideration to be received, depending upon the specific facts and circumstances.  The Company includes estimated variable consideration in the transaction price only to the extent it is probable that a significant reversal of revenue will not occur when the uncertainty is resolved.  The Company updates its estimate of variable consideration at the end of each reporting period to reflect changes in facts and circumstances.



The Company recognizes revenue at the point in time when it transfers control of the promised goods or services to the customer, which typically occurs once the product has shipped or has been delivered to the customer.  For certain customer warehousing agreements, delivery is deemed to have occurred when the customer pulls inventory out of the warehouse for use in their production.  Additionally, for certain customers, delivery is deemed to have occurred when items are delivered to bill and hold locations at the Company’s facility. 



The Company evaluated the nature of any guarantees or warranties related to its contracts with customers.  The Company determined that any such warranty is an assurance-type warranty that only covers the products’ compliance with agreed-upon specifications and does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications.



Certain contracts contain prepayment terms that result in liabilities for customer deposits.  Additionally, certain contracts provide for invoicing before all performance obligations have been fulfilled which results in deferred revenue.  Customer deposits and advance invoicing are recorded as contract liabilities on the Company’s consolidated balance sheet.



The Company generally expenses sales commission when incurred because the amortization period would have been one year or less.  These costs are recorded within selling and marketing expenses. 



The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected duration of one year or less. 



Based on the Company’s assessment, the implementation of Topic 606 will affect the timing of certain revenue related transactions primarily resulting from the earlier recognition of the Company's tooling revenue and costs.  Under legacy GAAP, the Company accounted for tooling as multiple element arrangements whereby revenue and cost were recognized over a period of time after the tool was completed.  Upon adoption of ASU 2014-09, tooling sales and costs will be recognized at the point in time upon which the tool is complete and the Company has satisfied all its performance obligations under the contract. 



The table below compares the affected lines on the consolidated statements of operations as presented to legacy GAAP treatment.







 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Six Months Ended



 

June 30,

 

June 30,



 

2018

 

2018

 

2018

 

2018



 

As
presented

 

Legacy
GAAP

 

As
presented

 

Legacy
GAAP

Net sales

 

$

5,320,426 

 

$

5,332,709 

 

$

10,439,474 

 

$

10,304,357 

Cost of sales

 

 

4,442,606 

 

 

4,449,942 

 

 

8,830,294 

 

 

8,736,630 

Gross profit

 

 

877,820 

 

 

882,767 

 

 

1,609,180 

 

 

1,567,727 



 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) from operations

 

 

117,891 

 

 

122,838 

 

 

26,755 

 

 

(14,698)

Net income (loss) before income tax provision (benefit)

 

 

33,681 

 

 

38,628 

 

 

(145,966)

 

 

(187,419)

Net income (loss) 

 

$

33,681 

 

$

38,628 

 

$

(145,966)

 

$

(187,419)

Comprehensive income (loss)

 

$

33,681 

 

$

38,628 

 

$

(145,966)

 

$

(187,419)

Earnings (loss) per share - basic

 

$

0.01 

 

$

0.01 

 

$

(0.05)

 

$

(0.07)

Earnings (loss) per share - diluted

 

$

0.01 

 

$

0.01 

 

$

(0.05)

 

$

(0.07)

Weighted average common shares outstanding - basic

 

 

2,847,642 

 

 

2,847,642 

 

 

2,844,889 

 

 

2,844,889 

Weighted average common shares outstanding - diluted

 

 

2,855,101 

 

 

2,855,101 

 

 

2,844,889 

 

 

2,844,889 



The table below compares the affected lines on the consolidated balance sheets as presented to legacy GAAP treatment.







 

 

 

 

 

 



 

 

 

 

 

 



 

June 30,

 

June 30,



 

2018

 

2018



 

As presented

 

Legacy GAAP

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

246,474 

 

$

280,141 

Total current assets

 

 

6,944,317 

 

 

6,977,984 

Other assets

 

 

4,135 

 

 

64,132 

Total assets

 

$

12,926,731 

 

$

13,020,395 

Liabilities and Shareholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Contract liabilities, current portion

 

$

736,570 

 

$

785,703 

Total current liabilities

 

 

4,188,096 

 

 

4,237,229 

Long-term liabilities:

 

 

 

 

 

 

Contract liabilities, non-current portion

 

 

 —

 

 

85,984 

Total long-term liabilities

 

 

3,767,167 

 

 

3,853,151 

Total liabilities

 

 

7,955,263 

 

 

8,090,380 

Shareholders’ equity:

 

 

 

 

 

 

Accumulated deficit

 

 

(3,696,143)

 

 

(3,737,596)

Total shareholders’ equity

 

 

4,971,468 

 

 

4,930,015 

Total liabilities and shareholders’ equity

 

$

12,926,731 

 

$

13,020,395 

 

3.  Earnings per Share ("EPS")



Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding.  The computation of diluted earnings (loss) per share is similar to the computation of basic earnings (loss) per share except that the denominator is increased to include the average number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.  In addition, the numerator is adjusted for any changes in net income (loss) that would result from the assumed conversions of those potential shares. 







 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Six Months Ended



 

June 30,

 

June 30,



 

2018

 

2017

 

2018

 

2017

Net income (loss)

 

$

33,681 

 

$

(511,453)

 

$

(145,966)

 

$

(809,890)

Net income (loss) available to common shareholders

 

$

33,681 

 

$

(511,453)

 

$

(145,966)

 

$

(809,890)

Basic EPS:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

2,847,642 

 

 

2,820,999 

 

 

2,844,889 

 

 

2,819,915 

Earnings (loss) per share - basic

 

$

0.01 

 

$

(0.18)

 

$

(0.05)

 

$

(0.29)

Diluted EPS:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

2,847,642 

 

 

2,820,999 

 

 

2,844,889 

 

 

2,819,915 

Assumed conversion of net common shares issuable
under stock option plans

 

 

3,796 

 

 

 —

 

 

 —

 

 

 —

Assumed conversion of net common shares issuable
under warrants

 

 

3,663 

 

 

 —

 

 

 —

 

 

 —

Weighted average common and common equivalent shares
outstanding, diluted

 

 

2,855,101 

 

 

2,820,999 

 

 

2,844,889 

 

 

2,819,915 

Earnings (loss) per share - diluted

 

$

0.01 

 

$

(0.18)

 

$

(0.05)

 

$

(0.29)

 

4.  Inventories



Inventories consist of the following:







 

 

 

 

 

 



 

 

 

 

 

 



 

June 30,

 

December 31,



 

2018

 

2017

Raw materials

 

$

1,120,619 

 

$

1,100,187 

Work-in-process

 

 

1,096,473 

 

 

822,244 

Finished goods

 

 

1,428,060 

 

 

1,490,768 

Total

 

$

3,645,152 

 

$

3,413,199 



Silver included in raw materials, work-in-process and finished goods inventory had an estimated cost of $483,039 and $536,963 as of June 30, 2018 and December 31, 2017, respectively.

 

5.  Property, Plant and Equipment, net



Property, plant and equipment, net consist of the following:







 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 



 

Asset Lives

 

June 30,

 

December 31,



 

(in years)

 

2018

 

2017

Machinery and equipment

 

3

to

15

 

$

17,559,355 

 

$

17,498,586 

Building and improvements

 

5

to

25

 

 

3,991,951 

 

 

3,986,715 

Vehicles

 

3

to

5

 

 

104,714 

 

 

90,713 

Furniture, fixtures, computers and software

 

3

to

5

 

 

1,593,184 

 

 

1,542,027 

Construction in progress

 

 

 

 

 

 

144,213 

 

 

17,412 

Total property, plant and equipment

 

 

 

 

 

 

23,393,415 

 

 

23,135,453 

Less: accumulated depreciation

 

 

 

 

 

 

(18,157,110)

 

 

(17,391,414)

Property, plant and equipment, net

 

 

 

 

 

$

5,236,305 

 

$

5,744,039 



For the three and six months ended June 30, 2018, the Company recorded depreciation expense of $370,909 and $765,696, respectively.  For the three and six months ended June 30, 2017, the Company recorded depreciation expense of $406,761 and $801,881, respectively.  



In January 2016, the Company entered into a Purchase and Sale Agreement (“Agreement”) to sell two unoccupied buildings, with a total of approximately 52,000 square feet, and land, at its Fitchburg, Massachusetts campus.   As a result, the Company has since classified the real estate as Assets Held for Sale.



The Company and the Buyer (the “Parties”), have since entered into multiple amendments which provided for, among other things, an extension of the expiration date of the agreement to June 2019 in exchange for monthly extension fees.



In January 2018, the Company was notified that the National Park Service of the Department of the Interior designated the area in which the buildings are located as a Historic District, which will enable the Buyer to proceed with securing historical tax credits as agreed between the Parties.



The closing is subject to permitting and approvals from the City of Fitchburg and the Commonwealth of Massachusetts and is expected to take place by the end of the first quarter of 2019.



At June 30, 2018 and December 31, 2017, the carrying value of the assets held for sale remains at $688,750, which approximates the fair value less the expected costs to sell.

 

6.  Intangible Assets, net



The Company assesses the impairment of long-lived assets and intangible assets with finite lives annually or whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. For the three and six months ended June 30, 2018 and 2017, the Company did not impair any intangible assets.



Intangible assets consist of the following:







 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

Estimated

 

June 30, 2018

 

December 31, 2017



 

Useful Life

 

 

 

 

Accumulated

 

 

 

 

 

 

 

Accumulated

 

 

 



 

(in years)

 

Gross

 

Amortization

 

Net

 

Gross

 

Amortization

 

Net

Patents and trademarks

 

10 

 

$

22,911 

 

$

10,609 

 

$

12,302 

 

$

22,911 

 

$

9,888 

 

$

13,023 

Patents and trademarks pending

 

 —

 

 

13,786 

 

 

 —

 

 

13,786 

 

 

13,786 

 

 

 —

 

 

13,786 

Trade names

 

15 

 

 

29,062 

 

 

1,926 

 

 

27,136 

 

 

29,062 

 

 

738 

 

 

28,324 

Total intangible assets

 

 

 

$

65,759 

 

$

12,535 

 

$

53,224 

 

$

65,759 

 

$

10,626 

 

$

55,133 



For the three and six months ended June 30, 2018, the Company recorded amortization expense of $933 and $1,909, respectively.  For the three and six months ended June 30, 2017, the Company recorded amortization expense of $547 and $986, respectively.



On July 3, 2018, the Company was awarded a U.S. Patent for an invention which improves the high-low pressure system in 40MM M212 casings used in military, law enforcement and other markets.  Under a multi-year exclusive supply agreement with the Company’s customer, Security Devices International, Inc., the patent rights and obligations are shared equally.



 

7.  Debt



The following table sets forth the items which comprise debt for the Company:





 

 

 

 

 

 



 

 

 

 

 

 



 

June 30,

 

December 31,



 

2018

 

2017

Revolving line of credit

 

$

1,307,954 

 

$

1,879,047 

Subordinated promissory notes

 

$

 —

 

$

350,000 



 

 

 

 

 

 

Total term notes payable, net of issuance costs

 

$

4,157,876 

 

$

4,346,194 

Less current portion, net

 

 

390,709 

 

 

367,779 

Term notes payable, non-current, net

 

 

3,767,167 

 

 

3,978,415 



 

 

 

 

 

 

Total short and long term debt, net

 

$

5,465,830 

 

$

6,575,241 



Bank Debt



On December 29, 2017, the Company entered into a three-year $9,500,000 asset based credit and security agreement (“credit agreement”), with a Massachusetts trust company, replacing the credit facility with the Company’s previous lender.  The credit agreement also provided funds with which to discharge the subordinated promissory notes. 



The credit agreement includes a revolving line of credit of up to $5.0 million (“Revolver”), a machinery and equipment term loan of $2.5 million (“Equipment Loan”) and a real estate term loan of $2.0 million (“Real Estate Loan” and together with the “Equipment Loan” the “Term Loans”).  The credit agreement contains both financial and non-financial covenants, and is secured by substantially all the assets of the Company.



Revolver



The Revolver is subject to certain borrowing base limitations, primarily related to conditions of the Company’s accounts receivable and inventory.  The agreement provides for a daily sweep of cash balances against the balance of the Revolver.  Amounts available to borrow under the Revolver are $1,557,941 at June 30, 2018.



The Revolver allows for interest only payments during the term of the facility with the full principal outstanding balance to be paid upon maturity on December 29, 2020.  Interest on all borrowings from the Revolver shall be equal to the Wall Street Journal prime rate (“Prime Rate”) plus 0.5% (5.50% at June 30, 2018).  In lieu of having interest charged at the Prime Rate, the Company has the option, on the last day of each month, (the “LIBOR Option”) to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.25% for the following month (5.34213% at June 30, 2018).  The interest rate will automatically convert back to the Prime Rate at the beginning of the next month unless the Company elects the LIBOR Option for the next month.  This Revolver carries a provision for a quarterly unused facility fee equal to 0.25% per annum of the average daily undisbursed face amount of the Revolver during the three months immediately preceding the applicable due date and has no prepayment penalty. 



Term Loans



The Equipment Loan requires monthly principal payments of approximately $29,762, payable on the first day of each month commencing February 1, 2018.  The Equipment Loan is based upon an 84 month amortization with a balloon payment of approximately $1,458,333 due and payable in full upon maturity on December 29, 2020. 



The Real Estate Loan requires monthly principal payments of approximately $8,333, payable on the first day of each month commencing February 1, 2018.  The Real Estate Loan is based upon a 240 month amortization with a balloon payment of approximately $1,708,333 due and payable in full upon maturity on December 29, 2020. 



Interest on the Term Loans shall be at such Wall Street Journal prime rate plus 0.75% (5.75% at June 30, 2018).  In lieu of having interest charged at the Prime Rate, the Company shall have a LIBOR Option, as described above, to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.5% for the following month (5.84213% at June 30, 2018). 



All interest on the Revolver and the Term Loans will be calculated based upon a year of 360 days for actual days elapsed.  Interest is payable monthly in arrears.  Upon the occurrence and during the continuation of an Event of Default, all interest will be increased by 2% above the per annum rate otherwise applicable thereto.  The Term Loans carry a prepayment penalty with respect to the prepayment of any portion of either Term Loan equal to 3%, 2%, and 1% of the amount prepaid in the first, second, and third years, respectively, of the credit agreement.  



This credit agreement contains covenants related to various matters including certain financial covenants, prohibitions on further borrowings and security interests, merger or consolidation, acquisitions, guarantees, sales of assets other than in the normal course of business, leasing, and payment of dividends. The lender has a security interest in substantially all assets and a mortgage encumbering certain real property.



Other Debt



Subordinated promissory notes



In December 2013, the Company completed a private offering in which the Company sold an aggregate of $500,000 in subordinated promissory notes and issued warrants to purchase 100,000 shares of common stock.  Three related parties participated in the private offering as follows:  REF Securities, LLP, and with Mr. Rodd E. Friedman, a director of the Company, a beneficial owner of approximately 12% of the Company’s common stock, invested $100,000 in the offering; the Chambers Medical Foundation (the “Foundation”), beneficial owner of approximately 11% of the Company’s common stock, invested $100,000 in the offering; and Mr. E.P. Marinos, then a director of the Company, invested $50,000 in the offering.  The Company’s Chairman of the Board is a co-trustee of the Foundation but has held no dispositive powers since his appointment as such.



On December 29, 2017, as part of entering into the credit agreement, the Company obtained funds to discharge the remaining $450,000 of subordinated debt.  On December 29, 2017, the Company paid one of the subordinated notes in the principal amount of $100,000.  The remaining five notes, totaling an aggregate principal amount of $350,000, were discharged on January 2, 2018, including the subordinated notes held by the three related parties mentioned above.  The Company carried $350,000 as restricted cash at December 31, 2017 for this purpose.



In connection with the private offering of subordinated promissory notes, the Company issued 100,000 warrants to purchase the Company's common stock, including 20,000 warrants to REF Securities, LLP, 20,000 warrants to the Foundation and 10,000 warrants to Mr. Marinos.  The warrants were initially exercisable through December 2016 at an exercise price of $3.51 per share.  In October 2016, in connection with the extension of the maturity dates of the subordinated promissory notes, the expiration date of the remaining unexercised 70,000 warrants was extended to December 31, 2018.  The discharge of the subordinated promissory notes as described above did not affect the maturity date of the warrants.  The exercise price remained unchanged at $3.51 per share.   The 70,000 warrants remain unexercised at June 30, 2018.

 

8.  Income Taxes



No provision for income taxes has been recorded in the three or six months ended June 30, 2018 or 2017, respectively.    Except for a benefit of an immaterial amount of federal alternative minimum tax credit, the Company continues to maintain a full valuation allowance against its deferred tax assets as of June 30, 2018 and December 31, 2017. 



At June 30, 2018, the Company has federal and state net operating loss carryforwards totaling $10,275,000 and $12,317,000, respectively, which begin to expire in 2031. The Company also has federal and state tax credit carryovers of $306,000 and $268,000 respectively. The federal and state tax credits begin to expire in 2027 and 2018, respectively. 

 

9.  Commitments and Contingencies



Legal matters



In the ordinary course of its business, the Company is involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material impact on the Company’s financial position or results of operations.



Off-balance sheet arrangements



Lease expense under all operating leases for the three months ended June 30, 2018 and 2017 was $6,008 and $5,884,   respectively.  For the six months ended June 30, 2018 and 2017, lease expense under all operating leases was $11,921 and $13,114, respectively. 

 

10.  Shareholders’ Equity



Stock options and share-based incentive plan



The following table sets forth the stock option transactions for the six months ended June 30, 2018:







 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

Weighted

 

 

 



 

 

 

Weighted

 

average

 

 

 



 

 

 

Average

 

remaining

 

Aggregate



 

Number of

 

Exercise

 

contractual

 

Intrinsic



 

options

 

Price

 

term (in years)

 

Value

Outstanding at December 31, 2017

 

205,500 

 

$

6.04 

 

6.07 

 

$

28,750 

Granted

 

90,000 

 

 

3.81 

 

 

 

 

 

Forfeited

 

(2,000)

 

 

3.81 

 

 

 

 

 

Outstanding at June 30, 2018

 

293,500 

 

$

5.37 

 

6.83 

 

$

10,188 

Exercisable at June 30, 2018

 

152,826 

 

$

6.38 

 

4.87 

 

$

10,188 

Exercisable at December 31, 2017

 

114,583 

 

$

6.42 

 

5.30 

 

$

20,551 



For the three months ended June 30, 2018 and 2017, share based compensation expense related to stock options amounted to $8,817 and $6,196, respectively.  For the six months ended June 30, 2018 and 2017, share based compensation expense related to stock options amounted to $23,187 and $21,167, respectively.  Share based compensation is included in general and administrative expenses.



For the three months ended June 30, 2018 and 2017, no options were granted or exercised.  For the three months ended June 30, 2018 and 2017, options forfeited were 2,000 and 4,000, respectively due to employee terminations. 



For the six months ended June 30, 2018, 90,000 options were granted with a fair value of $0.50 per share.  No options were granted in the six months ended June 30, 2017.  For the six months ended June 30, 2018 and 2017, no options were exercised.  For the six months ended June 30, 2018 and 2017, options forfeited were 2,000 and 4,000, respectively. 



Unrecognized stock based compensation expense as of June 30, 2018 and 2017 was $101,196 and $111,126, respectively. 



Warrants



For the three and six months ended June 30, 2018 and 2017, there were no warrants exercised. As of June 30, 2018, 70,000 warrants remain unexercised, including 20,000 held by the Company’s largest beneficial owner, REF Securities, LLP and with Mr. Rodd E. Friedman, a director of the Company, and 10,000 held by Mr. E. P. Marinos, a former director of the Company.  The warrants expire in December 2018.



Common Stock



For the three months ended June 30, 2018, the Company issued 5,242 shares of the Company’s common stock, with a fair value of $19,875 for director fees in lieu of cash payments.  For the three months ended June 30, 2017, the Company did not issue any shares. 



For the six months ended June 30, 2018, the Company issued 10,903 shares of the Company’s common stock, with a fair value of $39,750 for director fees in lieu of cash payments.  For the six months ended June 30, 2017, the Company issued 4,360 shares of the Company’s common stock, with a fair value of $11,250 for director fees in lieu of cash payments. 

 



 

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations



Forward-Looking Statements



This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. There are a number of factors that could cause the Company’s actual results to differ materially from those forecasted or projected in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The Company is under no obligation and does not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events.  More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 26, 2018.



Overview



Micron Solutions®, Inc., a Delaware corporation ("Micron Solutions”), through its wholly-owned Massachusetts subsidiary, Micron Products®, Inc. (“Micron” and together with Micron Solutions, the "Company"), is a diversified contract manufacturing organization (“CMO”) that produces highly-engineered, innovative medical device components requiring precision machining and injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, automotive and consumer product applications. The Company is engaged in the production and sale of silver/silver chloride coated and conductive resin sensors used as consumable component parts in the manufacture of integrated disposable electrophysiological sensors. These disposable medical devices are used worldwide in the monitoring of electrical signals in various medical applications. The Company's machining operations produce quick-turn, high volume patient-specific and off-the-shelf orthopedic implants and instruments.  The Company’s machining operations also include laser marking, automated polishing, passivation and coating. The Company has thermoplastic injection molding capabilities as well, and provides a full array of design, engineering, production services and management. The Company competes globally, with approximately forty-six percent of its revenue derived from exports.



Critical Accounting Policies



The critical accounting policies utilized by the Company in preparation of the accompanying financial statements are set forth in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. There have been no material changes to these policies since December 31, 2017, except for the implementation of ASU No. 2014-09, “Revenue from Contracts with Customers” as described in Note 2 to these financial statements.



Operating matters and liquidity



On December 29, 2017, the Company entered into a three-year asset based credit and security agreement (“credit agreement”), with a Massachusetts trust company, replacing the credit facility with the Company’s previous lender.  The credit agreement includes a revolving line of credit and term loans as further described in Note 7.  The agreement provides for daily cash sweeps against the Revolver.

In addition to providing funds to discharge all the indebtedness with the Company’s previous lender, the credit agreement provided $450,000 designated to discharge the outstanding subordinated promissory notes.  On December 29, 2017, one subordinated note in the principal balance of $100,000 was discharged in full.  The remaining five subordinated notes totaling an aggregate principal balance of $350,000 were discharged on January 2, 2018.

At June 30, 2018, the Company identified certain conditions and events which in the aggregate, despite the profitable quarter ended June 30, 2018, required management to perform an assessment of the Company’s ability to continue as a going concern. These conditions included the Company’s history of recurring losses from operations and the resulting reliance on outside financing to support operations.



Management’s analysis includes forecasting future revenues and cash flows, taking into consideration past performance and the requirements under the credit agreement. Revenue and cash flow forecasts are dependent on the Company’s ability to fill booked orders from existing customers, and its ability to close new and expanded business. Based on management’s analysis, the Company expects to generate sufficient cash flows to fulfill its payment obligations over the next twelve months from the date these financial statements were issued.

Results of Operations



The following table sets forth, for the periods indicated, the percentages of the net sales represented by certain items reflected in the Company's statements of operations.







 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Six Months Ended



 

June 30,

 

June 30,



 

2018 

 

 

2017 

 

 

2018 

 

 

2017 

 

Net sales 

 

100.0 

%

 

100.0 

%

 

100.0 

%

 

100.0 

%

Cost of sales 

 

83.5 

 

 

92.9 

 

 

84.6 

 

 

90.3 

 

Gross profit 

 

16.5 

 

 

7.1 

 

 

15.4 

 

 

9.7 

 

Selling and marketing 

 

3.8 

 

 

4.4 

 

 

3.8 

 

 

4.7 

 

General and administrative 

 

9.9 

 

 

10.3 

 

 

10.9 

 

 

11.0 

 

Research and development 

 

0.5 

 

 

0.5 

 

 

0.5 

 

 

0.5 

 

Other expense

 

1.6 

 

 

1.4 

 

 

1.7 

 

 

1.1 

 

Income (loss) before income tax provision (benefit)

 

0.7 

 

 

(9.5)

 

 

(1.5)

 

 

(7.6)

 

Income tax provision (benefit)

 

 —

 

 

 —

 

 

 —

 

 

 —

 

Net income (loss)

 

0.7 

%

 

(9.5)

%

 

(1.5)

%

 

(7.6)

%



Net Sales







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

Net sales

 

2018

 

2017

 

$ Change

 

% Change

Three months ended June 30,

 

$

5,320,426 

 

$

5,390,726 

 

$

(70,300)

 

(1.3)%



The decrease in consolidated net sales for the three months ended June 30, 2018 versus the prior year period was due primarily to a decrease in net sales of tooling.  This was partly offset by increased net sales of sensors, machined orthopedic implant components and instruments, as well as thermoplastic injection molding.



For the three months ended June 30, 2018, net sales of tooling decreased 88.0% when compared to the same period in the prior year.  The decrease was due primarily to the impact in the second quarter of 2017 of revenue from new tools for customers in the automotive and medical device industries.



Partly offsetting the decrease in net sales for the three months ended June 30, 2018, was a 0.7% increase in net sales of sensors when compared to the same prior year period, due primarily to customer and product mix.  Additionally, silver surcharge billed decreased 0.1% due in part to product mix and the price of silver maintaining comparable levels when compared with the same period in the prior year.



Also partly offsetting the decrease in net sales for the three months ended June 30, 2018, was a 10.0% increase in net sales of machined orthopedic implant components and instruments when compared to the same prior year period.  The increase was due primarily to increased demand of implant components from two customers.  Additionally, the Company realized increased net sales from two new customers.  These increases were partially offset by decreased demand from another customer who vertically integrated their machining and polishing of knee components beginning in the third quarter of 2017 and decreased demand of hip stem implant components. 



Also partly offsetting the decrease in net sales for the three months ended June 30, 2018, was a 2.2% increase in net sales of thermoplastic injection molding when compared to the same period in the prior year.  This was due primarily to increased net sales to customers in the medical device as well as the military and law enforcement industries, partly offset by decreased net sales from customers in the automotive and consumer product industries.







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

Net sales

 

2018

 

2017

 

$ Change

 

% Change

Six months ended June 30,

 

$

10,439,474 

 

$

10,655,703 

 

$

(216,229)

 

(2.0)%



The decrease in consolidated net sales for the six months ended June 30, 2018 versus the prior year period was due to a decrease in net sales of thermoplastic injection molding and tooling.  This was partly offset by increased net sales of sensors and machined orthopedic implant components and instruments.



For the six months ended June 30, 2018, net sales of thermoplastic injection molding decreased 12.4% when compared to the same prior year period.  The decrease was due in part to the vertical integration of a single medical device customer, partly offset by net sales to a new thermoplastic injection molded product to a long time sensor customer, who is expanding its product offerings.  Additionally, net sales decreased in the military and law enforcement, automotive and consumer product industries. 



For the six months ended June 30, 2018, net sales of tooling decreased 58.1% when compared to 2017, due primarily to decreased tooling for the automotive, medical device and military and law enforcement industries.



Partly offsetting the decreases above for the six months ended June 30, 2018, was a 6.8% increase in net sales of sensors due largely to a 6.2% increase in volume compared to the same period in 2017.  Silver surcharge billed increased 7.1% based largely on volume as the price of silver maintained levels comparable to the same prior year period.



Also partly offsetting the decreases for the six months ended June 30, 2018, was a 10.6% increase in net sales of machined orthopedic implant components and instruments.  The increase was due primarily to increased demand of knee implant components from two customers.  Additionally, the Company realized increased net sales from two new customers.  The increases were partially offset by decreased demand from a customer who vertically integrated their machining of knee implant components beginning in the third quarter of 2017.  Increases were also partly offset by decreased demand of hip stems and conical implant components. 



Gross Profit







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

2018

 

2017

 

$ Change

 

% Change

Three months ended June 30,

 

$

877,820 

 

$

381,837 

 

$

495,983 

 

129.9% 

As a percentage of sales

 

 

16.5% 

 

 

7.1% 

 

 

 

 

 



The increase in consolidated gross profit for the three months ended June 30, 2018 versus the prior year period was due to an increase in gross profit from machined orthopedic implant components and instruments, thermoplastic injection molding, and sensors, partly offset by a decrease in gross profit from tooling.



The increase in consolidated gross profit for the three months ended June 30, 2018 versus the prior year period, was due in part to a 385.0% increase in gross profit from machined orthopedic implant components and instruments.  The increase was due in part to an increase in net sales as noted above.  Additionally, the Company refined its production processes resulting in reduced rework, scrap, tooling, labor, expediting charges from suppliers, shift premiums and overtime to meet customer delivery requirements when compared to the second quarter of 2017.  Gross profit as a percentage of sales increased 22.7 percentage points.



The increase in consolidated gross profit for the three months ended June 30, 2018 versus the prior year period, was also due in part to a 0.8% increase from thermoplastic injection molding.  The increase was due in part to increased net sales, however, gross profit as a percentage of sales decreased 0.4 percentage points due in part to the vertical integration of production by a higher margin customer as well as increased scrap.



The increase in consolidated gross profit for the three months ended June 30, 2018 was also due in part to an increase in gross profit from sensors as a result of customer mix and improved raw materials yield and efficiency improvements in both the molding and plating operations. 



The increases above were partially offset by a 76.1% decrease in gross profit from tooling.  The decrease was primarily the result of lower net sales in the three months ended June 30, 2018.  However, gross profit as a percentage of sales increased 9.8 percentage points over the same period last year.



During the three months ended June 30, 2018, the Company decreased other indirect manufacturing overhead expenses by 6.1% when compared to the same period in the prior year.  This was largely due to improved management of payroll related costs.







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

2018

 

2017

 

$ Change

 

% Change

Six months ended June 30,

 

$

1,609,180 

 

$

1,035,211 

 

$

573,969 

 

55.4% 

As a percentage of sales

 

 

15.4% 

 

 

9.7% 

 

 

 

 

 



The increase in consolidated gross profit for the six months ended June 30, 2018 versus the prior year period was due to an increase in gross profit from machined orthopedic implant components and instruments as well as sensors, partly offset by decreases in thermoplastic injection molding and net tooling. 



Additionally, the increase in consolidated gross profit for the six months ended June 30, 2018, when compared to the same prior year period, was due in part to a 221.3% increase in gross profit from machined orthopedic implant components and instruments. The increase was due in part to an increase in net sales as noted above.  Additionally, the Company refined its production processes resulting in reduced rework, scrap, tooling, labor, expediting charges from suppliers, shift premiums and overtime to meet customer delivery requirements when compared to the second quarter of 2017.  Gross profit as a percentage of sales increase 18.4 percentage points.



Partly offsetting the increase was a decrease in consolidated gross profit from thermoplastic injection molding of 22.8% due primarily to lower net sales as described above.  Additionally, the lower gross profit was partly the result of a decrease in gross profit as a percentage of sales which decreased 3.6 percentage points due in part to the impact the vertical integration of production by a customer with a higher profit margin as well as increased scrap over the same prior year period.



The increase in consolidated gross profit for the six months ended June 30, 2018, when compared to the same prior year period, was due in part to an increase in gross profit from sensors due largely to increased sales as noted above, which was driven by both increased volume and customer mix as well as improved raw materials yield and efficiency improvements in both the molding and plating operations. 

 

Also partly offsetting the increase above was a decrease of 37.2% from net tooling due largely to lower net sales, however, gross profit as a percentage of sales increased 11.5 percentage points.



Selling and Marketing



The Company's consolidated selling and marketing expenses amounted to $204,036 (3.8% of net sales) for the three months ended June 30, 2018 as compared to $234,820 (4.4% of net sales) for the three months ended June 30, 2017, a decrease of $30,785, or 13.1%.



For the three months ended June 30, 2018, the decrease was primarily due to decreased compensation of $29,840, due in part to compensation adjustments implemented in the third quarter of 2017 as well as the use of independent manufacturer’s sales representatives.  Commissions also decreased $5,461 accordingly.  The decrease is also due in part to lower office supplies expense of $2,676, lower marketing expenses of $2,807, and a decrease of $4,650 in depreciation expense due to certain fixed assets becoming fully depreciated since the second quarter of 2017.  Partly offsetting the decreases were increased travel expenses of $11,929 as a result of international travel in the second quarter of 2018.



The Company's consolidated selling and marketing expenses amounted to $394,576 (3.8% of net sales) for the six months ended June 30, 2018 as compared to $500,693 (4.7% of net sales) for the six months ended June 30, 2017, a decrease of $106,117, or 21.2%.

For the six months ended June 30, 2018, the decrease was primarily due to decreased compensation of $85,090 due partly to compensation adjustments implemented in the third quarter of 2017 as well as the use of independent manufacturer’s sales representatives in the first half of 2018.  Commissions decreased $5,967.  Additionally, advertising and marketing expenses were lower by $7,428 due in part to reduced attendance at trade shows.  Office and computer supplies expense were lower by $6,020.  Professional services decreased due to lower recruiting agency fees partly offset by cloud based lead generation services. Depreciation expense was lower by $2,871 due to certain fixed assets becoming fully depreciated over the prior year.  Travel expenses during the period were lower by $2,084.



General and Administrative



The Company's consolidated general and administrative expenses decreased to $529,092 (9.9% of net sales) for the three months ended June 30, 2018 as compared to $552,678 (10.3% of net sales) for the three months ended June 30, 2017, a decrease of $23,586, or 4.3%. 



The decrease in general and administrative expenses for the three months ended June 30, 2018 when compared to 2017 is due in part to a $66,337 decrease in compensation expenses due in part to compensation adjustments for salaried employees and executives implemented in the third quarter of 2017.  Compensation also decreased due to the outsourcing of the Company’s IT and environmental, health and safety functions.  Additionally, general liability insurance decreased $9,594 due in part to adjustments to revenue based premiums.  Bad debt expense decreased approximately $8,000 due in part to the impact of a $6,000 increase in bad debt reserve in the second quarter of 2017.  



The decreases above for the three months ended June 30, 2018, when compared to 2017, were partly offset by $19,453 for non-recurring professional consulting fees related to the implementation of new revenue recognition accounting guidance.  Additionally, the decreases were partly offset by increases in professional and outside consulting services of $16,091 for outsourcing the IT function, $8,313 for outsourcing the environmental, health and safety function, $7,009 for legal fees and $5,038 for a bank field examination.



The Company's consolidated general and administrative expenses decreased to $1,133,127 (10.9% of net sales) for the six months ended June 30, 2018 as compared to $1,169,508 (11.0% of net sales) for the six months ended June 30, 2017, a decrease of $36,381, or 3.1%. 



The decrease in general and administrative expenses for the six months ended June 30, 2018 compared to 2017 is due largely to decreased compensation expense of $95,206 due in part to compensation adjustments for salaried employees and executives implemented in the third quarter of 2017.  Compensation also decreased due to the outsourcing of the Company’s IT and environmental, health and safety functions. 



The decreases above for the six months ended June 30, 2018, when compared to the same period in 2017, were partly offset by $31,913 for non-recurring professional consulting fees related to the implementation of new revenue recognition accounting guidance.  Additionally, the decreases were partly offset by increases in professional and outside consulting services of $16,773 for outsourcing the IT function, $10,407 for outsourcing the environmental, health and safety function, $8,198 for legal fees and $5,038 for a bank field examination.



Research and Development



The Company's consolidated research and development expenses decreased to $26,801 (0.5% of net sales) for the three months ended June 30, 2018 as compared to $28,344 (0.5% of net sales) for the three months ended June 30, 2017, a decrease of $1,543, or 5.4%. 



The Company's consolidated research and development expenses decreased to $54,722 (0.5% of net sales) for the six months ended June 30, 2018 as compared to $57,640 (0.5% of net sales) for the six months ended June 30, 2017, a decrease of $2,917, or 5.1%. 



The decreases for the three and six months ended June 30, 2018 and 2017 were due to salary reductions implemented in the third quarter of 2017.



Other Expense, net



Other expense, net increased to $84,210 for the three months ended June 30, 2018, as compared to $77,448, for the three months ended June 30, 2017, an increase of $6,762.  The increase in other expense, net was due largely to an $8,587 increase in interest expense which was due to $10,231 of deferred financing amortization as a result of the new credit agreement, partly offset by the impact of lower outstanding borrowings on the Revolver.



Other expense, net increased to $172,721 for the six months ended June 30, 2018, as compared to $117,260, for the six months ended June 30, 2017, an increase of $55,461.  The increase in other expense, net was due largely to a $41,698 increase in interest expense due in part to higher interest rates and $18,755 of deferred financing amortization as a result of the new credit agreement.  Additionally, other income decreased $13,763 partly due to the impact of a gain of $21,554 on the sales of fixed assets in the first half of 2017 offset by an increase of $12,000 in extension fees collected in relation to the sale of assets held for sale.



Income Tax Provision



The tax provisions for the three and six months ended June 30, 2018 and 2017 attributable to the U.S. federal and state income taxes are $0. The Company’s combined federal and state effective income tax rate for the three and six months ended June 30, 2018 and 2017 of 0% is due to the deferred tax assets being nearly fully reserved for with a valuation allowance.



Earnings (Loss) Per Share



Consolidated basic and diluted earnings per share for the three months ended June 30, 2018 was $0.01 per share as compared to a loss of $0.18 per share for the same period in 2017, an increase in earnings per share of $0.19. The increase in earnings per share for the three months ended June 30, 2018, is due largely to an increase in gross profit of $495,983 and a decrease of $55,913 in operating expenses compared to the prior year period. 



Consolidated basic and diluted loss per share for the six months ended June 30, 2018 was $0.05 per share as compared to a loss of $0.29 per share for the same period in 2017, a decrease in loss per share of $0.24. The decrease in loss per share for the six months ended June 30, 2018, is due largely to an increase in gross profit of $573,969 and a decrease of $145,416 in operating expenses compared to the prior year period. 



Off-Balance Sheet Arrangements



Lease expense under all operating leases for the three months ended June 30, 2018 and 2017 was $6,008 and $5,884, respectively.  For the six months ended June 30, 2018 and 2017, lease expense under all operating leases was $11,921 and $13,114, respectively. 

 

Liquidity and Capital Resources



Working capital was $2,756,221 as of June 30, 2018, as compared to $2,548,692 at December 31, 2017, an increase of $207,529.  The increase in working capital is due primarily to increases in accounts receivable and inventory and a decrease in accounts payable, partly offset by an increase in contract liabilities related to tooling contracts.  Cash on hand decreased $956,988, due largely to net payments on the Revolver of $571,093 and the discharge of subordinated debt of $350,000. 



Trade accounts receivable, net of allowance for doubtful accounts, were $3,052,691 and $2,595,248 at June 30, 2018 and December 31, 2017, respectively, an increase of $457,443.  The increase is due largely to higher sales in the second quarter of 2018 compared to the fourth quarter of 2017. 



Inventories were $3,645,152 as of June 30, 2018, as compared to $3,413,199 at December 31, 2017, an increase of $231,953.  The increase was due primarily to an increase in work-in-process of $274,229 driven largely by an increase in tooling in-process.



Accounts payable were $1,326,070 and $1,534,349 at June 30, 2018 and December 31, 2017, respectively, a decrease of $208,279 due largely to the timing of disbursements.  Accrued expenses and other current liabilities increased $125,061 in part due to increased accruals for payroll, interest expense and certain employee training programs.  Contract liabilities increased $310,113 due to increased customer deposits and advance invoicing for in-process tooling. 



Capital equipment expenditures were $181,702 for the six months ended June 30, 2018, due to expenditures related to computer software and hardware, as well as thermoplastic injection molding and quality inspection equipment compared to $759,546 for the six months ended June 30, 2017 for machinery and equipment primarily for the contract manufacturing of machined orthopedic implants and instruments as well as thermoplastic injection molding.



At June 30, 2018, the Company’s total debt was $5,465,830 as compared to $6,575,241 at December 31, 2017, a decrease of $1,109,409.  The decrease is due largely to net payments on the Revolver of $571,093 and the discharge of $350,000 of subordinated debt.  Additionally, the Company made $190,476 of payments on term debt. 



The Company has a three-year credit agreement with a Massachusetts trust company.  The credit agreement includes a revolving line of credit of up to $5.0 million, a machinery and equipment term loan of $2.5 million and a real estate term loan of $2.0 million.  The credit agreement contains both financial and non-financial covenants, and is secured by substantially all assets of the Company and a mortgage encumbering certain real property. 



The Revolver allows for interest only payments during the term of the facility with the full principal outstanding balance to be paid upon maturity on December 29, 2020.  Interest on all borrowings from the Revolver shall be equal to the Wall Street Journal prime rate (“Prime Rate”) plus 0.5% (5.50% at June 30, 2018).  In lieu of having interest charged at the Prime Rate, the Company has the option, on the last day of each month, (the “LIBOR Option”) to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.25% for the following month.  The interest rate will automatically convert back to the Prime Rate at the beginning of the next month unless the Company elects the LIBOR Option for the next month.  This Revolver carries a provision for a quarterly unused facility fee equal to 0.25% per annum of the average daily undisbursed face amount of the Revolver during the three months immediately preceding the applicable due date and has no prepayment penalty. 



The Revolver is subject to certain borrowing base limitations, primarily related to conditions of the Company’s accounts receivable and inventory.  The credit agreement provides for a daily sweep of cash balances against the balance of the Revolver.  Amounts available to borrow under the Revolver are $1,557,941 at June 30, 2018.



The Term Loans require aggregate monthly principal payments of approximately $38,095, payable on the first day of each month.  The Equipment Loan is based upon an 84 month amortization with a balloon payment of approximately $1,458,333 due and payable in full upon maturity on December 29, 2020.  The Real Estate Loan is based upon a 240 month amortization with a balloon payment of approximately $1,708,333 due and payable in full upon maturity on December 29, 2020. 



Interest on the Term Loans shall be at the Wall Street Journal prime rate plus 0.75% (5.75% at June 30, 2018).  In lieu of having interest charged at the Prime Rate, the Company shall have a LIBOR Option, as described above, to have interest charged at a rate of interest equal to the daily one-month LIBOR plus 3.5% for the following month. 



All interest on the credit agreement will be calculated based upon a year of 360 days for actual days elapsed.  Interest is payable monthly in arrears.  Upon the occurrence and during the continuation of an Event of Default, all interest will be increased by 2% above the per annum rate otherwise applicable thereto.  The Term Loans carry a prepayment penalty with respect to the prepayment of any portion of either Term Loan equal to 3%, 2%, and 1% of the amount prepaid in the first, second, and third years, respectively, of the credit agreement.  



In December 2013, the Company completed a private offering in which the Company sold an aggregate of $500,000 in subordinated promissory notes and issued warrants to purchase 100,000 shares of common stock.  Three related parties participated in the private offering as follows:  REF Securities, LLP, and with Mr. Rodd E. Friedman, a current director of the Company, a beneficial owner of approximately 12% of the Company’s common stock, invested $100,000 in the offering; the Chambers Medical Foundation (the “Foundation”), beneficial owner of approximately 11% of the Company’s common stock, invested $100,000 in the offering; and Mr. E.P. Marinos, then a director of the Company, invested $50,000 in the offering.  The Company’s Chairman of the Board is a co-trustee of the Foundation but has held no dispositive powers since his appointment as such.



On December 29, 2017, as part of entering into the credit agreement, the Company obtained funds to discharge the remaining $450,000 of subordinated debt.  On December 29, 2017, the Company paid one of the subordinated notes in the principal amount of $100,000.  The remaining five notes, totaling an aggregate principal amount $350,000, were discharged on January 2, 2018, including the subordinated notes held by the three related parties mentioned above.  The Company carried $350,000 as restricted cash at December 31, 2017 for this purpose.



No dividends were declared or paid in the three or six months ended June 30, 2018 and 2017.



The Company believes that cash flows from its operations, together with its existing working capital, booked orders, the credit agreement and other resources, will be sufficient to fund operations at current levels and repay debt obligations over the next twelve months from the date these financial statements were issued; however, there can be no assurance that the Company will be able to do so.



Summary of Changes in Cash Position



As of June 30, 2018, the Company had cash on hand of $0, as all the Company’s cash is swept daily against the Revolver in accordance with the Company’s credit arrangement.  For the six months ended June 30, 2018, net cash provided by operating activities was $365,172.  Net cash used in investing activities for the six months ended June 30, 2018 was $181,702. Net cash used in financing activities for the six months ended June 30, 2018 was $1,140,458. The net cash flows for the six months ended June 30, 2018 are discussed in further detail below.



Operating Cash Flows 



For the six months ended June 30, 2018, net cash provided by operating activities was $365,172. Cash provided by operating activities was primarily impacted by an increase of $310,113 in contract liabilities related to customer deposits for tooling, a decrease of $186,311 in prepaid expenses and other current assets as well as an increase of $125,061 in accrued expenses and other current liabilities.  Cash provided by operating activities was also impacted by non-cash add-backs for depreciation and amortization of $767,605, share-based compensation of $62,937 and non-cash interest expense of $31,047. 



Partly offsetting the above sources of cash was cash used due to increases of $457,443 in accounts receivable and $308,214 in inventory as well as a decrease in accounts payable of $208,279.



Investing Cash Flows



For the six months ended June 30, 2018, net cash used in investing activities was $181,702. The net cash used was for capital expenditures of $181,702, primarily for computer software and hardware, as well as thermoplastic injection molding and quality inspection equipment.



Financing Cash Flows



For the six months ended June 30, 2018, net cash used in financing activities was $1,140,458. Cash was used for net payments on the revolver of $571,093, the discharge of $350,000 of subordinated debt, payments of $190,476 on term notes payable and $28,889 related to debt issuance costs. 

 

Item 3.  Quantitative and Qualitative Disclosures about Market Risk



Not Applicable.



Item 4.  Controls and Procedures



Evaluation of Disclosure Controls and Procedures



Our principal executive officer and principal financial officer (“the Certifying Officers”) have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)).  Based on such evaluation, our Certifying Officers have concluded the Company's disclosure controls and procedures, as of the end of the period covered by this report, were effective.



The effectiveness of a system of disclosure controls and procedures is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the soundness of internal controls, and fraud. Due to such inherent limitations, there can be no assurance that any system of disclosure controls and procedures will be successful in preventing all errors or fraud, or in making all material information known in a timely manner to the appropriate levels of management.



Changes in Internal Control over Financial Reporting



During the three months ended June 30, 2018, there have been no changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

3


 

PART II - OTHER INFORMATION



Item 6. Exhibit Index





 

 

 

 

Exhibit
Number

 

Description of Exhibit

 

Page

3.0

 

Certificate of Incorporation (incorporated by reference to the Company’s Registration Statement on Form S-18 as filed with the Commission in April 1988, Registration Statement No. 33-20945-FW).

 

 

3.1

 

Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K as filed with the Commission on July 1, 2011).

 

 

3.2

 

Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q as filed with the Commission on August 13, 2015).

 

 

4.0

 

Form of Certificate evidencing shares of the Company's Common Stock (incorporated by reference to the Company’s Registration Statement on Form S-18 as filed with the Commission in April 1988, Registration Statement No. 33-20945-FW).

 

 

4.1

 

Certificate of Amendment of Certificate of Incorporation dated March 8, 2017 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the Commission on March 14, 2017).

 

 

4.10*

 

2010 Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-8 as filed with the Commission on May 6, 2010, Registration Statement No. 333-166600).

 

 

4.11

 

Form of Subordinated Note (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the Commission on December 23, 2013).

 

 

4.12

 

Form of Subordination Agreement (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K as filed with the Commission on December 23, 2013)

 

 

4.13

 

Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K as filed with the Commission on December 23, 2013).

 

 

4.14

 

Form of Amended and Restated Subordinated Promissory Note (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the Commission on October 17, 2016).

 

 

4.15

 

Form of Amendment No. 1 to Warrant to Purchase Shares of Common Stock (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K as filed with the Commission on October 17, 2016).

 

 

10.51

 

Loan and Security Agreement between UniBank for Savings and Arrhythmia Research Technology, Inc. and Micron Products, Inc. dated March 29, 2013 (incorporated by reference to Exhibit 10.51 to the Company’s Quarterly Report on Form 10-Q as filed with the Commission on July 1, 2013).

 

 

10.61

 

Fourth Amendment to Loan and Security Agreement and Commercial Equipment Line of Credit Promissory Note dated June 19, 2015 (incorporated by reference to Exhibit 10.61 to the Company’s Quarterly Report on Form 10-Q as filed with the Commission on August 13, 2015).

 

 

10.62

 

Fifth Amendment to Loan and Security Agreement dated as of November 15, 2016 (incorporated by reference to Exhibit 10.62 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 as filed with the Commission on March 22, 2017).

 

 

10.63

 

Commercial Term Promissory Note dated November 15, 2016 (incorporated by reference to Exhibit 10.63 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 as filed with the Commission on March 22, 2017).

 

 

10.64

 

Commercial Equipment Line of Credit Promissory Note dated November 15, 2016 (incorporated by reference to Exhibit 10.64 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 as filed with the Commission on March 22, 2017).

 

 

10.65*

 

Executive Incentive Plan (incorporated by reference to Exhibit 10.65 to the Company's Current Report on Form 8-K as filed with the Commission on December 6, 2016).

 

 

10.66*

 

Employment Agreement between the Company and Salvatore Emma, Jr. dated as of January 1, 2017 (incorporated by reference to Exhibit 10.66 to the Company's Annual Report on Form 10-K for fiscal year ended December 31, 2016 as filed with the Commission on March 22, 2017).